According to FutureWise analysis the market for Near-Patient Molecular Solutions in 2023 is US$ 3.5 billion, and is expected to reach US$ 6.58 billion by 2031 at a CAGR of 8.22%.
The near patient molecular solution, also known as point-of-care diagnosis, is a technology that enables patients to diagnose and monitor their health at the point of care. Various innovations in healthcare, such as basic health monitoring smartphone apps, wearable devices, and biosensors, make it easier for patients to monitor their health. In contrast to conventional lab-based testing, we intend to provide patients with easy access to testing solutions, with quick turnaround times and accurate results. Increasing rates of diseases such as cardiovascular diseases and diabetes in developing countries, growing demand for home-based point-of-care devices, and the availability of easy-to-use devices are driving growth in the near patient molecular solution market.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Near-Patient Molecular Solutions Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Near-Patient Molecular Solutions Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.